ResApp Health Ltd's (ASX:RAP) shares have plunged 76% to $0.074 in the first 90 minutes of trade after the company reported preliminary top-line results from the SMARTCOUGH-C Study.
The study is for the diagnosis of childhood respiratory disease using cough sounds.
Analysis of the SMARTCOUGH-C study data revealed many issues in the quality of cough recordings and that many patients were treated before their coughs were recorded.
ResApp intends to continue its Australian adult programme in parallel and initiate a US adult clinical study this US winter.
Company Name · Code · Last · Change · Volume
ResApp Health Ltd · RAP · $0.070 · -77.42% · 79,370,373
Jacka Resources Ltd · JKA · $0.003 · -25% · 22,600
Latin Resources Ltd · LRS · $0.004 · -20% · 3,423,002
Uranium Equities Ltd · UEQ · $0.005 · -16.67% · 610,000
Memphasys Ltd · MEM · $0.005 · -16.67% · 3,478,010
Eclipse Metals Ltd · EPM · $0.005 · -16.67% · 150,000
Hastings Technology Metals Ltd · HAS · $0.160 · -15.79% · 284,061
SportsHero Ltd · SHO · $0.032 · -15.79% · 50,000
Cohiba Mining · CHK · $0.011 · -15.39% · 1,750,880
Aruma Resources Ltd · AAJ · $0.006 · -14.29% · 120,000